PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'MerckSerono S.p.A, Guidonia di Montecello, Italy.\', \'EMD Serono, Billerica, Massachusetts, USA.\', \'Ares Trading SA/Merck SA Switzerland, Aubonne, Switzerland.\', \'Merck KGaA, Darmstadt, Germany.\', \'Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.\', \'IAVI, New York, New York, USA.\', \'IAVI, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA.\', \'Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/bit.27995
?:hasPublicationType
?:journal
  • Biotechnology and bioengineering
is ?:pmid of
?:pmid
?:pmid
  • 34796474
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 165
is ?:relation_isRelatedTo_publication of
?:title
  • Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34796474>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34796474>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all